報價延遲最少15分鐘:2025/08/11 03:32 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.19 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.75/-19.36
|
|
企業價值
163.02M
|
| 資產負債 |
|
每股賬面淨值
0.61
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
65.30M
|
|
每股收益
1.53
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/11 03:32 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. |
